Location History:
- South Glenfield Harrison, NJ (US) (1987)
- Harrison, NY (US) (1987 - 1990)
Company Filing History:
3 out of 512 
2 out of 559 
1 out of 832,812 Years Active: 1987-2025
Title: Bo Dupont: Innovator in Immunotherapy and Monoclonal Antibodies
Introduction
Bo Dupont is a notable inventor based in Harrison, NY (US), recognized for his significant contributions to the fields of immunotherapy and monoclonal antibodies. With a total of six patents to his name, Dupont has made strides in developing innovative methods for treating cancer and other diseases.
Latest Patents
One of Dupont's latest patents focuses on the use of the IL-15/IL-15Rα complex in generating antigen-specific T cells for adoptive immunotherapy. This invention provides methods for generating these T cells for therapeutic administration to patients with pathogens or cancer. The patent outlines the use of soluble IL-15/IL-15Rα complexes in cell culture during the ex vivo sensitization of T cells to the antigen. Additionally, it describes the generation of antigen-specific T cells and methods for treating patients using these cells. Another significant patent involves a new monoclonal antibody, mAb 4C, which recognizes a specific antigen, Leu 200, found in human hematopoietic tissues. This antibody precipitates a series of glycoproteins with varying molecular weights and has potential applications in leukemia and hematopoietic cell differentiation.
Career Highlights
Throughout his career, Bo Dupont has worked with prestigious institutions, including the Sloan Kettering Institute for Cancer Research and the Memorial Sloan Kettering Cancer Center. His work has been instrumental in advancing research in cancer treatment and immunology.
Collaborations
Dupont has collaborated with notable colleagues, including Yasuo Morishima and Nancy Collins, contributing to the advancement of research in his field.
Conclusion
Bo Dupont's innovative work in immunotherapy and monoclonal antibodies has made a significant impact on medical research and treatment options for patients. His contributions continue to shape the future of cancer therapy and immunological advancements.